Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04545658
Status:
COMPLETED
Last Update Posted:
2020-09-11
First Post:
2020-08-10
Brief Title:
Prediction of Esophageal and Lung Toxicities After Radiation Chemo Therapy
Sponsor:
University Hospital Brest
Organization:
University Hospital Brest
Study Overview
Official Title:
Prediction of Esophageal and Lung Toxicities After Radiation Chemo Therapy for Lung Cancer Management
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PTOP-RT
Brief Summary:
Chemo-radiotherapy is the gold standard therapeutic treatment for patients with locally advanced lung cancer non accessible or ineligible for surgery While some progress occurred regarding progression free survival and overall survival thanks to recent advances ie durvalumab prediction of pulmonary and esophageal toxicity remains insufficiently accurate Current dose-volume histograms DVH do not account for spatial dose distribution and strict application of current dose constraints does not prevent toxicity events in some of the treated patients The goal of this work was to investigate the added predictive value of the radiomics approach applied to dose maps regarding acute and late toxicity in both lungs and the esophagus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None